PGC-1α induces SPP1 to activate macrophages and orchestrate functional angiogenesis in skeletal muscle

Circulation Research

Volumn 115, Issue 5, 2014, Pages 504-517

  Rowe, Glenn C ^a   Raghuram, Srilatha ^a   Jang, Cholsoon ^a   Nagy, Janice A ^b   Patten, Ian S ^a   Goyal, Amrita ^a   Chan, Mun Chun ^a   Liu, Laura X ^a   Jiang, Aihua ^a   Spokes, Katherine C ^b   Beeler, David ^b   Dvorak, Harold ^b   Aird, William C ^b   Arany, Zolt ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

angiogenesis effect; cytokines; gene action regulation; genetic therapy; intercellular signaling peptides and proteins; macrophages; muscle, skeletal; osteopontin; peripheral arterial disease; PGC 1alpha protein, mouse

Indexed keywords

ADENOVIRUS VECTOR; ALBUMIN I 125; CD31 ANTIGEN; GREEN FLUORESCENT PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOINFORMATICS; BLOOD FLOW; CAPILLARY DENSITY; CELL MIGRATION; CELL STRUCTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETES MELLITUS; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GASTROCNEMIUS MUSCLE; GENE OVEREXPRESSION; HINDLIMB; HINDLIMB ISCHEMIA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIMB ISCHEMIA; MACROPHAGE ACTIVATION; MICRO-COMPUTED TOMOGRAPHY; MOUSE; MUSCULAR DYSTROPHY; MYOTUBE; NONHUMAN; PERICYTE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; SMOOTH MUSCLE FIBER; TIBIALIS ANTERIOR MUSCLE; VASCULAR PATENCY; VASCULARIZATION;

EID: 85027923529     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.303829     Document Type: Article

References (77)

1. Booth FW, Thomason DB. Molecular and cellular adaptation of muscle in response to exercise: perspectives of various models. Physiol Rev. 1991;71:541-585.
2. Egginton S. Invited review: activity-induced angiogenesis. Pflugers Arch. 2009;457:963-977.
3. Bloor CM. Angiogenesis during exercise and training. Angiogenesis. 2005;8:263-271. (Pubitemid 41759151)
4. Prior BM, Yang HT, Terjung RL. What makes vessels grow with exercise training? J Appl Physiol (1985). 2004;97:1119-1128. (Pubitemid 39121441)
5. Mason SD, Rundqvist H, Papandreou I, Duh R, McNulty WJ, Howlett RA, Olfert IM, Sundberg CJ, Denko NC, Poellinger L, Johnson RS. HIF- 1alpha in endurance training: suppression of oxidative metabolism. Am J Physiol Regul Integr Comp Physiol. 2007;293:R2059-R2069. (Pubitemid 350085685)
6. Arany Z. PGC-1 coactivators and skeletal muscle adaptations in health and disease. Curr Opin Genet Dev. 2008;18:426-434. (Pubitemid 50283238)
7. Finck BN, Kelly DP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest. 2006;116:615-622. (Pubitemid 43326866)
8. Calvo JA, Daniels TG, Wang X, Paul A, Lin J, Spiegelman BM, Stevenson SC, Rangwala SM. Muscle-specific expression of PPARgamma coactivator- 1alpha improves exercise performance and increases peak oxygen uptake. J Appl Physiol (1985). 2008;104:1304-1312.
9. Lin J, Wu H, Tarr PT, Zhang CY, Wu Z, Boss O, Michael LF, Puigserver P, Isotani E, Olson EN, Lowell BB, Bassel-Duby R, Spiegelman BM. Transcriptional co-activator PGC-1 alpha drives the formation of slowtwitch muscle fibres. Nature. 2002;418:797-801.
10. Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, Girnun G, Cooper M, Laznik D, Chinsomboon J, Rangwala SM, Baek KH, Rosenzweig A, Spiegelman BM. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature. 2008;451:1008-1012. (Pubitemid 351301733)
11. Chinsomboon J, Ruas J, Gupta RK, Thom R, Shoag J, Rowe GC, Sawada N, Raghuram S, Arany Z. The transcriptional coactivator PGC-1alpha mediates exercise-induced angiogenesis in skeletal muscle. Proc Natl Acad Sci U S A. 2009;106:21401-21406.
12. Wende AR, Schaeffer PJ, Parker GJ, Zechner C, Han DH, Chen MM, Hancock CR, Lehman JJ, Huss JM, McClain DA, Holloszy JO, Kelly DP. A role for the transcriptional coactivator PGC-1alpha in muscle refueling. J Biol Chem. 2007;282:36642-36651.
13. May D, Gilon D, Djonov V, Itin A, Lazarus A, Gordon O, Rosenberger C, Keshet E. Transgenic system for conditional induction and rescue of chronic myocardial hibernation provides insights into genomic programs of hibernation. Proc Natl Acad Sci U S A. 2008;105:282-287.
14. Rowe GC, Patten IS, Zsengeller ZK, El-Khoury R, Okutsu M, Bampoh S, Koulisis N, Farrell C, Hirshman MF, Yan Z, Goodyear LJ, Rustin P, Arany Z. Disconnecting mitochondrial content from respiratory chain capacity in PGC-1-deficient skeletal muscle. Cell Rep. 2013;3:1449-1456.
15. Nagy JA, Dvorak AM, Dvorak HF. Vascular hyperpermeability, angiogenesis, and stroma generation. Cold Spring Harb Perspect Med. 2012;2:a006544.
16. Handschin C, Kobayashi YM, Chin S, Seale P, Campbell KP, Spiegelman BM. PGC-1alpha regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy. Genes Dev. 2007;21:770-783. (Pubitemid 46572357)
17. Couffinhal T, Silver M, Zheng LP, Kearney M, Witzenbichler B, Isner JM. Mouse model of angiogenesis. Am J Pathol. 1998;152:1667-1679. (Pubitemid 28275025)
18. Cox CA, Amaral J, Salloum R, Guedez L, Reid TW, Jaworski C, John-Aryankalayil M, Freedman KA, Campos MM, Martinez A, Becerra SP, Carper DA. Doxycycline's effect on ocular angiogenesis: an in vivo analysis. Ophthalmology. 2010;117:1782-1791.
19. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298-307.
20. Karamysheva AF. Mechanisms of angiogenesis. Biochemistry (Mosc). 2008;73:751-762.
21. Merrilees MJ, Beaumont B, Scott LJ. Comparison of deposits of versican, biglycan and decorin in saphenous vein and internal thoracic, radial and coronary arteries: correlation to patency. Coron Artery Dis. 2001;12:7-16. (Pubitemid 32108646)
22. Plante GE, Chakir M, Ettaouil K, Lehoux S, Sirois P. Consequences of alteration in capillary permeability. Can J Physiol Pharmacol. 1996;74:824-833. (Pubitemid 26426572)
23. Bulfield G, Siller WG, Wight PA, Moore KJ. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci U S A. 1984;81:1189-1192. (Pubitemid 14171480)
24. Tafuro S, Ayuso E, Zacchigna S, Zentilin L, Moimas S, Dore F, Giacca M. Inducible adeno-associated virus vectors promote functional angiogenesis in adult organisms via regulated vascular endothelial growth factor expression. Cardiovasc Res. 2009;83:663-671.
25. Stewart DJ, Kutryk MJ, Fitchett D, Freeman M, Camack N, Su Y, Della Siega A, Bilodeau L, Burton JR, Proulx G, Radhakrishnan S; NORTHERN Trial Investigators. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol Ther. 2009;17:1109-1115.
26. Su H, Takagawa J, Huang Y, Arakawa-Hoyt J, Pons J, Grossman W, Kan YW. Additive effect of AAV-mediated angiopoietin-1 and VEGF expression on the therapy of infarcted heart. Int J Cardiol. 2009;133: 191-197.
27. Kutcher ME, Herman IM. The pericyte: cellular regulator of microvascular blood flow. Microvasc Res. 2009;77:235-246.
28. Raza A, Franklin MJ, Dudek AZ. Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol. 2010;85:593-598.
29. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Jung S, Yung S, Chimenti S, Landsman L, Abramovitch R, Keshet E. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell. 2006;124:175-189. (Pubitemid 43069318)
30. Duvall CL, Weiss D, Robinson ST, Alameddine FM, Guldberg RE, Taylor WR. The role of osteopontin in recovery from hind limb ischemia. Arterioscler Thromb Vasc Biol. 2008;28:290-295. (Pubitemid 351161202)
31. Nomiyama T, Perez-Tilve D, Ogawa D, Gizard F, Zhao Y, Heywood EB, Jones KL, Kawamori R, Cassis LA, Tschöp MH, Bruemmer D. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest. 2007;117: 2877-2888 (Pubitemid 47529618)
32. Darland DC, Massingham LJ, Smith SR, Piek E, Saint-Geniez M, D'Amore PA. Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev Biol. 2003;264:275-288. (Pubitemid 37393463)
33. Ding R, Darland DC, Parmacek MS, D'Amore PA. Endothelialmesenchymal interactions in vitro reveal molecular mechanisms of smooth muscle/pericyte differentiation. Stem Cells Dev. 2004;13:509-520. (Pubitemid 39473581)
34. Arefieva TI, Kukhtina NB, Antonova OA, Krasnikova TL. MCP-1-stimulated chemotaxis of monocytic and endothelial cells is dependent on activation of different signaling cascades. Cytokine. 2005;31: 439-446. (Pubitemid 41242768)
35. Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK, Oppenheim JJ, Murphy WJ. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood. 2000;96:34-40. (Pubitemid 30456447)
36. Weber KS, Nelson PJ, Gröne HJ, Weber C. Expression of CCR2 by endothelial cells: implications for MCP-1 mediated wound injury repair and In vivo inflammatory activation of endothelium. Arterioscler Thromb Vasc Biol. 1999;19:2085-2093. (Pubitemid 29422239)
37. Ma J, Wang Q, Fei T, Han JD, Chen YG. MCP-1 mediates TGF-betainduced angiogenesis by stimulating vascular smooth muscle cell migration. Blood. 2007;109:987-994. (Pubitemid 46220643)
38. Troidl K, Schaper W. Arteriogenesis versus angiogenesis in peripheral artery disease. Diabetes Metab Res Rev. 2012;28(suppl 1):27-29.
39. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004;56:549-580. (Pubitemid 39658463)
40. Reginato S, Gianni-Barrera R, Banfi A. Taming of the wild vessel: promoting vessel stabilization for safe therapeutic angiogenesis. Biochem Soc Trans. 2011;39:1654-1658.
41. Giacca M, Zacchigna S. VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond. Gene Ther. 2012;19:622-629.
42. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438:967-974. (Pubitemid 43093963)
43. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest. 1999;103: 1231-1236. (Pubitemid 29218292)
44. Karvinen H, Pasanen E, Rissanen TT, Korpisalo P, Vähäkangas E, Jazwa A, Giacca M, Ylä-Herttuala S. Long-term VEGF-A expression promotes aberrant angiogenesis and fibrosis in skeletal muscle. Gene Ther. 2011;18:1166-1172.
45. Germani A, Di Campli C, Pompilio G, Biglioli P, Capogrossi MC. Regenerative therapy in peripheral artery disease. Cardiovasc Ther. 2009;27:289-304.
46. Mikroulis D, Papanas N, Maltezos E, Bougioukas G. Angiogenic growth factors in the treatment of peripheral arterial disease. Curr Vasc Pharmacol. 2007;5:195-209.
47. Schalch P, Rahman GF, Patejunas G, Goldschmidt RA, Carbray J, Retuerto MA, Kim D, Esser K, Crystal RG, Rosengart TK. Adenoviral-mediated transfer of vascular endothelial growth factor 121 cDNA enhances myocardial perfusion and exercise performance in the nonischemic state. J Thorac Cardiovasc Surg. 2004;127:535-540. (Pubitemid 38176660)
48. Rajagopalan S, Mohler E III, Lederman RJ, Saucedo J, Mendelsohn FO, Olin J, Blebea J, Goldman C, Trachtenberg JD, Pressler M, Rasmussen H, Annex BH, Hirsch AT; Regional Angiogenesis With Vascular Endothelial Growth Factor trial. Regional Angiogenesis with Vascular Endothelial Growth Factor (VEGF) in peripheral arterial disease: design of the RAVE trial. Am Heart J. 2003;145:1114-1118. (Pubitemid 36688266)
49. Semenza GL. Therapeutic angiogenesis: another passing phase? Circ Res. 2006;98:1115-1116. (Pubitemid 43948095)
50. Carmeliet P. VEGF gene therapy: stimulating angiogenesis or angiomagenesis? Nat Med. 2000;6:1102-1103.
51. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, Fine J, McCluskey ER; VIVA Investigators. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation. 2003;107:1359-1365. (Pubitemid 36350732)
52. Rajagopalan S, Mohler ER III, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, Blebea J, Macko J, Kessler PD, Rasmussen HS, Annex BH. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation. 2003;108:1933-1938. (Pubitemid 37296537)
53. Mäkinen K, Manninen H, Hedman M, Matsi P, Mussalo H, Alhava E, Ylä-Herttuala S. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther. 2002;6:127-133. (Pubitemid 36124280)
54. Muona K, Mäkinen K, Hedman M, Manninen H, Ylä-Herttuala S. 10-year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb. Gene Ther. 2012;19:392-395.
55. Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ, Annex BH; TRAFFIC Investigators. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet. 2002;359: 2053-2058 (Pubitemid 34680967)
56. Sarkar K, Fox-Talbot K, Steenbergen C, Bosch-Marcé M, Semenza GL. Adenoviral transfer of HIF-1alpha enhances vascular responses to critical limb ischemia in diabetic mice. Proc Natl Acad Sci U S A. 2009;106:18769-18774.
57. Creager MA, Olin JW, Belch JJ, Moneta GL, Henry TD, Rajagopalan S, Annex BH, Hiatt WR. Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation. 2011;124:1765-1773.
58. Rezvani HR, Ali N, Nissen LJ, Harfouche G, de Verneuil H, Taïeb A, Mazurier F. HIF-1 in epidermis: oxygen sensing, cutaneous angiogenesis, cancer, and non-cancer disorders. J Invest Dermatol. 2011;131:1793-1805.
59. Coulon C, Georgiadou M, Roncal C, De Bock K, Langenberg T, Carmeliet P. From vessel sprouting to normalization: role of the prolyl hydroxylase domain protein/hypoxia-inducible factor oxygen-sensing machinery. Arterioscler Thromb Vasc Biol. 2010;30:2331 2336.
60. Semenza GL. Regulation of vascularization by hypoxia-inducible factor 1. Ann N Y Acad Sci. 2009;1177:2-8.
61. Semenza GL. HIF-1 inhibitors for cancer therapy: from gene expression to drug discovery. Curr Pharm Des. 2009;15:3839-3843.
62. Sica A. Role of tumour-associated macrophages in cancer-related inflammation. Exp Oncol. 2010;32:153-158.
63. Sica A. Macrophages give Gas(6) to cancer. Blood. 2010;115:2122-2123.
64. Alexander KA, Chang MK, Maylin ER, Kohler T, Müller R, Wu AC, Van Rooijen N, Sweet MJ, Hume DA, Raggatt LJ, Pettit AR. Osteal macrophages promote in vivo intramembranous bone healing in a mouse tibial injury model. J Bone Miner Res. 2011;26:1517-1532.
65. Murdoch C, Muthana M, Lewis CE. Hypoxia regulates macrophage functions in inflammation. J Immunol. 2005;175:6257-6263. (Pubitemid 41598863)
66. Lewis C, Murdoch C. Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am J Pathol. 2005;167:627-635. (Pubitemid 41216349)
67. Murdoch C, Lewis CE. Macrophage migration and gene expression in response to tumor hypoxia. Int J Cancer. 2005;117:701-708. (Pubitemid 41598819)
68. Senger DR, Ledbetter SR, Claffey KP, Papadopoulos-Sergiou A, Peruzzi CA, Detmar M. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol. 1996;149:293-305. (Pubitemid 26231000)
69. Chae S, Jun HO, Lee EG, Yang SJ, Lee DC, Jung JK, Park KC, Yeom YI, Kim KW. Osteopontin splice variants differentially modulate the migratory activity of hepatocellular carcinoma cell lines. Int J Oncol. 2009;35:1409-1416.
70. Senger DR, Perruzzi CA. Cell migration promoted by a potent GRGDScontaining thrombin-cleavage fragment of osteopontin. Biochim Biophys Acta. 1996;1314:13-24. (Pubitemid 26395494)
71. Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev. 2008;19:333-345.
72. Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M, Lindmark-Mänsson H. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:1087-1097. (Pubitemid 46984943)
73. Weber GF. The cancer biomarker osteopontin: combination with other markers. Cancer Genomics Proteomics. 2011;8:263-288.
74. Rittling SR. Osteopontin in macrophage function. Expert Rev Mol Med. 2011;13:e15.
75. Lyle AN, Joseph G, Fan AE, Weiss D, Landázuri N, Taylor WR. Reactive oxygen species regulate osteopontin expression in a murine model of postischemic neovascularization. Arterioscler Thromb Vasc Biol. 2012;32:1383-1391.
76. Fantin A, Vieira JM, Gestri G, Denti L, Schwarz Q, Prykhozhij S, Peri F, Wilson SW, Ruhrberg C. Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood. 2010;116:829-840.
77. Gustafsson T. Vascular remodelling in human skeletal muscle. Biochem Soc Trans. 2011;39:1628-1632.